Clinical Partners LLC

1. Eli Lilly and Company $699,506 50 payments
2. AbbVie, Inc. $572,147 476 payments
3. Amgen Inc. $505,665 29 payments
4. Sun Pharmaceutical Industries Inc. $196,878 105 payments
5. Ucb SA $157,246 13 payments
6. Janssen Research & Development, LLC $149,104 75 payments
7. Sanofi US Services Inc. $98,423 22 payments
8. Pfizer Inc. $76,719 27 payments
9. Bausch Health US, LLC $72,226 13 payments
10. VYNE Pharmaceuticals Inc. $49,344 11 payments

1. Psor-025/20200063 (Discreet) $227,877 5 payments
2. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $167,685 6 payments
3. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $140,067 4 payments
4. A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis $111,451 89 payments
5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $101,148 6 payments
6. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa $91,750 37 payments
7. Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis(PSOR-025) $90,363 5 payments
8. A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp $87,021 34 payments
9. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $79,016 41 payments
10. Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis (PSOR-025) $78,937 3 payments

1. Professional salary support $87,021 34 payments
2. Overhead $150 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.